LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) announced its inclusion in the Russell Microcap Index, effective after the close of U.S. markets on June 26, 2026, with the reconstituted index taking effect at the opening of trading on June 29, 2026. The company stated that joining the widely followed benchmark is expected to increase its visibility among institutional investors and investment products that track Russell indexes.
The milestone reflects progress under LIXTE's new leadership and strategic direction, supporting its efforts to build a platform focused on AI energy infrastructure equipment and services. The Russell Microcap Index is reconstituted annually and measures the performance of smaller publicly traded U.S. companies.
LIXTE Biotechnology Holdings, Inc. is primarily a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development. Its lead compound, LB-100, is a first-in-class clinical PP2A inhibitor that has shown tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. This approach is part of a pioneering effort in an entirely new field of cancer biology known as activation lethality.
Through its wholly owned subsidiary, Liora Technologies Europe Ltd., LIXTE is also pioneering the development of electronically controlled proton therapy systems for treating tumors. Liora's proprietary flagship technology, the LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy.
The inclusion in the Russell Microcap Index is a significant milestone for LIXTE as it seeks to broaden its investor base and gain greater recognition in the financial community. For institutional investors and fund managers who track Russell indexes, LIXT's addition means the stock will be automatically included in portfolios that mirror the index, potentially driving increased demand and liquidity.
This development also signals LIXTE's strategic pivot toward AI energy infrastructure, a move that could open new growth avenues beyond its core biotechnology focus. The company's dual emphasis on cancer therapeutics and advanced energy technology positions it uniquely in the market, though the success of this diversification will depend on execution and market adoption.
The full press release is available at https://ibn.fm/r6l81. More information about Liora Technologies can be found at www.lioratechnologies.com.
